Linked Life Data

10946886

Source:http://linkedlifedata.com/resource/pubmed/id/10946886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2000-8-31
pubmed:abstractText
Exaggerated GH and reduced insulin-like growth factor I (IGF-I) levels are common features in anorexia nervosa (AN). A reduction of the negative IGF-I feedback could account, in part, for GH hypersecretion. To ascertain this, we studied the effects of recombinant human (rh)IGF-I on spontaneous and GH-releasing hormone (GHRH)-stimulated GH secretion in nine women with AN [body mass index, 14.1 +/- 0.6 kg/m2] and in weight matched controls (normal weight). Mean basal GH concentrations (mGHc) and GHRH (2.0 microg/kg, iv) stimulation were significantly higher in AN. rhIGF-I administration (20 microg/kg, sc) significantly reduced mGHc in AN (P < 0.01), but not normal weight, and inhibited peak GH response to GHRH in both groups; mGHc and peak GH, however, persisted at a significantly higher level in AN. Insulin, glucose, and IGFBP-1 basal levels were similar in both groups. rhIGF-I inhibited insulin in AN, whereas glucose remained unaffected in both groups. IGFBP-1 increased in both groups (P < 0.05), with significantly higher levels in AN. IGFBP-3 was under basal conditions at a lower level in AN (P < 0.05) and remained unaffected by rhIGF-I. This study demonstrates that a low rhIGF-I dose inhibits, but does not normalize, spontaneous and GHRH-stimulated GH secretion in AN, pointing also to the existence of a defective hypothalamic control of GH release. Moreover, the increased IGFBP-1 levels might curtail the negative IGF-I feedback in AN.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0021-972X
pubmed:author
pubmed:issnType
Print
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2805-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:10946886-Adolescent, pubmed-meshheading:10946886-Adult, pubmed-meshheading:10946886-Anorexia Nervosa, pubmed-meshheading:10946886-Blood Glucose, pubmed-meshheading:10946886-Estradiol, pubmed-meshheading:10946886-Feedback, pubmed-meshheading:10946886-Female, pubmed-meshheading:10946886-Follicle Stimulating Hormone, pubmed-meshheading:10946886-Growth Hormone-Releasing Hormone, pubmed-meshheading:10946886-Human Growth Hormone, pubmed-meshheading:10946886-Humans, pubmed-meshheading:10946886-Injections, Subcutaneous, pubmed-meshheading:10946886-Insulin, pubmed-meshheading:10946886-Insulin-Like Growth Factor Binding Protein 1, pubmed-meshheading:10946886-Insulin-Like Growth Factor I, pubmed-meshheading:10946886-Luteinizing Hormone, pubmed-meshheading:10946886-Recombinant Proteins, pubmed-meshheading:10946886-Reference Values
pubmed:year
2000
pubmed:articleTitle
Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa.
pubmed:affiliation
Department of Internal Medicine, University of Turin, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't